Becton, Dickinson and Company
Medical technology company.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Becton, Dickinson's stock with a target price of $271.01, indicating strong growth potential.
Financial Health
Becton, Dickinson and Company is effectively generating strong revenue and cash flow, with healthy profit margins.
Dividend
Becton, Dickinson's dividend yield of 2.38% indicates a reasonable return for investors seeking dividends. If you invested $1000 you would be paid $23.80 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BDX
Healthcare Titans: Brazil Growth vs Currency Volatility
Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.
Published: October 14, 2025
Explore BasketPharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: October 12, 2025
Explore BasketHealthcare Innovation: MedTech Giants Portfolio 2025
Growing demand for advanced healthcare in Africa highlights the global companies at the forefront of medical technology innovation. This theme offers exposure to US and EU-listed industry leaders in robotic surgery, diagnostic imaging, and other medical devices.
Published: September 22, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring Revenue Base
BDX earns steady income from disposables and consumables which can smooth earnings, though results can still vary with hospital budgets and competition.
Global Healthcare Exposure
Sales span hospitals, labs and research centres worldwide, offering diversification but exposing the company to currency and regulatory risks.
Innovation & M&A
R&D and targeted acquisitions help expand the product pipeline and market share, though integration and regulatory hurdles can affect outcomes.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Thermo Fisher Scientific, Inc.
Thermo Fisher provides a range of services and products that help customers advance their research, solve complex analytical challenges, improve patient diagnostics, and increase laboratory productivity.
Intuitive Surgical, Inc.
A healthcare company that develops, manufactures, and markets robotic-assisted surgical systems for procedures in multiple specialties
